Extra-intestinal malignancies in inflammatory bowel diseases: An update with emphasis on MDCT and MR imaging features

Dohan, Anthony; Faraoun, S.A.; Barral, Matthias; Guerrache, Youcef; Boudiaf, Mourad; Dray, Xavier; Hoeffel, Christine; Allez, Matthieu; Farges, Olivier; Beaugerie, Laurent; Aparicio, Thomas; Marteau, Pierre-François; Fishman, Elliot K.; Lucidarme, O.; Eveno, Clarisse; Pocard, Marc; Dautry, Raphaël; Soyer, Philippe

doi:10.1016/j.diii.2015.02.009

Cited by 11 publications

(11 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the general population, UC patients are significantly more likely to develop leukemia, with a standardized incidence rate of 2.0 (95% confidence interval [CI], 1.31-3.06). 57,58 In CD patients, there is an increased risk for lymphoma, especially non-Hodgkin lymphoma, with a standardized incidence rate of 1.42 (95% CI, 1.16-1.73). 58 Thiopurines were shown to increase the incidence of non-Hodgkin lymphoma after kidney transplantation.…”

Section: Inflammatory Bowel Disease and Hematological Malignanciesmentioning

confidence: 99%

“…57,58 In CD patients, there is an increased risk for lymphoma, especially non-Hodgkin lymphoma, with a standardized incidence rate of 1.42 (95% CI, 1.16-1.73). 58 Thiopurines were shown to increase the incidence of non-Hodgkin lymphoma after kidney transplantation. 59 Similar observations have been reported in patients with IBD.…”

Section: Inflammatory Bowel Disease and Hematological Malignanciesmentioning

confidence: 99%

See 1 more Smart Citation

Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease

Chang

et al. 2018

Clinical Colorectal Cancer

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) with its 2 most common entities, ulcerative colitis and Crohn's disease, causes an increased risk of developing intestinal cancers. In fact, malignancies are the second most common cause of death after cardiovascular diseases in both sexes of patients with IBD. Risk factors for colorectal cancer in IBD correlate with the duration of the disease, extent of disease, the association with primary sclerosing cholangitis, family history, and early age at onset. Patients with IBD also have an increased risk for developing a variety of extraintestinal malignancies. In particular, lymphomas, mostly non-Hodgkin lymphomas and skin cancers, are more frequently observed in IBD patients. Longstanding inflammation and the degree of immunosuppression as a result of IBD treatment appear to be the main driving factors for IBD-related carcinogenesis. This review provides an update on the clinical and pathological features of IBD-related intestinal and extraintestinal malignancies.

show abstract

Section: Inflammatory Bowel Disease and Hematological Malignanciesmentioning

confidence: 99%

Section: Inflammatory Bowel Disease and Hematological Malignanciesmentioning

confidence: 99%

Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease

Chang

et al. 2018

Clinical Colorectal Cancer

View full text Add to dashboard Cite

show abstract

“…While most cholangiocarcinomas occurs sporadically, chronic biliary inflammation is a well known risk factor. Additional risk factors include primary sclerosing cholangitis (associated with ulcerative colitis in up to 86% of patients), choledochal cyst, familial polyposis, hepatolithiasis, congenital hepatic fibrosis, clonorchiasis, and a history of exposure to thorotrast (2,5). Diagnostic imaging, coupled with a high degree of clinical suspicion, play a critical role in timely diagnosis, staging, and evaluation for surgical resectability (6,7).…”

Section: Introductionmentioning

confidence: 99%

Multimodality imaging of intrahepatic cholangiocarcinoma

Fábrega-Foster¹,

Ghasabeh²,

Pawlik³

et al. 2017

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinomas account for approximately 20% of cases of cholangiocarcinomas.Three growth patterns or morphologic subtypes exist, including mass-forming, periductal-infiltrating, and intraductal-growth subtypes. Knowledge of these morphologic subtypes and their radiologic appearance aids in timely diagnosis, a key to optimizing patient outcomes. The morphologic variability of intrahepatic cholangiocarcinomas has a direct impact on the diagnostic sensitivity and specificity of various diagnostic imaging modalities, including ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP), and positron emission tomography (PET).The following review emphasizes optimal imaging technique for each of these modalities and reviews the imaging appearance of each morphologic subtype of intrahepatic cholangiocarcinoma.

show abstract

“…In addition, a relationship of incidence of hepatic damage in patients with inflammatory diseases such as ulcerative colitis (17) has been found recently, which may be due to the passage of bacteria or endotoxins from the intestine to liver, that produces an inflammation of the liver and hepatobiliary damage, this condition is specifically termed cholangitis (18,19). In patients with NAFLD the damage derived from UC can be a factor of susceptibility for progress to non-alcoholic steatohepatitis (NASH).…”

Section: Denitrase Activity Of Debaryomyces Hansenii Reduces the Oxidmentioning

confidence: 99%

Denitrase activity of Debaryomyces�hansenii reduces the oxidized compound 3‑nitrotyrosine in mice liver with colitis

et al. 2019

View full text Add to dashboard Cite

The oxidation of tyrosine to 3-nitrotyrosine is irreversible, and due to this characteristic, 3-nitrotyrosine is used as a marker for oxidative stress in a range of diverse chronic and degenerative diseases. It has been established that the yeast Debaryomyces hansenii (D. hansenii) can assimilate free 3-nitrotyrosine as unique source of nitrogen, and during saline stress, has a high denitrase activity to detoxify this compound in a reaction that involves the liberation of nitrogen dioxide from 3-nitrotyrosine. However, until now it has not been determined whether D. hansenii can detoxify protein-bound 3-nitrotyrosine such as nitrated proteins present in different chronic illnesses. TThe aim of the present study was to evaluate the denitrase activity of D. hansenii to reduce 3-nitrotyrosine from liver proteins of mice with colitis. Firstly, the levels of reactive oxygen species of liver tissue of colitic and control mice were measured by the reaction with the 2'7'-dichlorofluorescein diacetate. Denitrase activity of D. hansenii was evaluated by incubating cell extracts of the yeast with protein extracts from livers of mice with colitis. Following incubation, 3-nitrotyrosine was measured, and to corroborate that denitrase reaction had occurred, the production of nitrites was measured. In samples of liver tissue from mice with colitis, the maximum levels of reactive oxygen species were up to two times higher compared with the control livers. Following the incubation of colitic liver samples with cell extracts of D. hansenii, it was observed that 3-nitrotyrosine decreased to the basal concentration of control liver samples, and that the concentration of nitrites was increased. These results indicate that denitrase of D. hansenii extracts can effectively detoxify 3-nitrotyrosine bound to proteins and that the extracts could be used to decrease protein oxidation damage in chronic degenerative diseases.

show abstract

Extra-intestinal malignancies in inflammatory bowel diseases: An update with emphasis on MDCT and MR imaging features

Cited by 11 publications

References 114 publications

Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease

Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease

Multimodality imaging of intrahepatic cholangiocarcinoma

Denitrase activity of Debaryomyces�hansenii reduces the oxidized compound 3‑nitrotyrosine in mice liver with colitis

Contact Info

Product

Resources

About